| 2026-08-14 | Press release | Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update |
| 2026-07-16 | Press release | Jasper Therapeutics Announces Merger with Kira Pharmaceuticals |
| 2026-06-01 | Press release | Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value |
| 2026-05-14 | Press release | Jasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update |
| 2026-03-30 | Press release | Jasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update |
| 2026-02-24 | Press release | Jasper Therapeutics to Present at 46th Annual TD Cowen Healthcare Conference |
| 2026-01-08 | Press release | Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria |
| 2026-01-07 | Press release | Jasper Therapeutics Appoints Jeet Mahal as Chief Executive Officer to Lead Next Phase of Clinical Growth |
| Press release | Jasper Therapeutics to Present at 39th Annual J.P. Morgan Virtual Healthcare Conference |
| Press release | Jasper Therapeutics Initiates New Clinical Trial with National Cancer Institute to Evaluate JSP191 in GATA2-related Myel |
| Press release | Jasper Therapeutics to Host Webcast to Review Updated 90-day Data from Phase 1 Clinical Trial of JSP191 That is Being Pr |
| Press release | Jasper Therapeutics Doses First Patient in Phase 1 Clinical Trial of JSP191 as Conditioning Agent for Patients with Myel |
| Press release | Jasper Therapeutics Closes Transaction With Amplitude Healthcare Acquisition Corporation, Creating a Publicly Traded Bio |
| Press release | Jasper Therapeutics Announces Updated 90-day Data from Phase 1 Clinical Trial of JSP191 as Targeted Stem Cell Conditioni |
| Press release | Jasper Therapeutics Announces Positive Data from Phase 1 Clinical Trial of JSP191 as Targeted Stem Cell Conditioning Age |
| Press release | Jasper Therapeutics Announces Orphan Drug and Rare Pediatric Disease Designations for JSP191 for Conditioning Treatment |
| Press release | Jasper Therapeutics Announces New Clinical Trial with the National Institute of Allergy and Infectious Diseases to Evalu |
| Press release | Jasper Therapeutics Announces Launch of New Clinical Trial with National Heart, Lung, and Blood Institute to Evaluate JS |
| Press release | Jasper Therapeutics Announces Data from First Transplant-naive Patient in Phase 1 Clinical Trial of JSP191 as Conditioni |
| Press release | Jasper Therapeutics and Graphite Bio Announce Collaboration to Evaluate JSP191 as Conditioning Regimen for Novel Gene Re |
| Press release | Jasper Therapeutics and Amplitude Healthcare Acquisition Corporation Announce Merger to Create a Publicly Listed Leading |